SG11201607706SA - Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer - Google Patents
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancerInfo
- Publication number
- SG11201607706SA SG11201607706SA SG11201607706SA SG11201607706SA SG11201607706SA SG 11201607706S A SG11201607706S A SG 11201607706SA SG 11201607706S A SG11201607706S A SG 11201607706SA SG 11201607706S A SG11201607706S A SG 11201607706SA SG 11201607706S A SG11201607706S A SG 11201607706SA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- tyrosine kinase
- kinase inhibitors
- benzimidazole derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968225P | 2014-03-20 | 2014-03-20 | |
PCT/US2015/021455 WO2015143148A1 (en) | 2014-03-20 | 2015-03-19 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201607706SA true SG11201607706SA (en) | 2016-10-28 |
Family
ID=52997514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607706SA SG11201607706SA (en) | 2014-03-20 | 2015-03-19 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
Country Status (16)
Country | Link |
---|---|
US (3) | US10005765B2 (en) |
EP (2) | EP3119762B9 (en) |
JP (3) | JP6577012B2 (en) |
KR (2) | KR102416358B1 (en) |
CN (3) | CN114989140A (en) |
AU (1) | AU2015231202B9 (en) |
CA (2) | CA2943220C (en) |
DK (1) | DK3119762T3 (en) |
ES (1) | ES2891734T3 (en) |
IL (3) | IL291000B2 (en) |
MX (2) | MX2016012097A (en) |
PT (1) | PT3119762T (en) |
RU (2) | RU2741914C2 (en) |
SG (1) | SG11201607706SA (en) |
TW (2) | TWI683813B (en) |
WO (1) | WO2015143148A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
TWI659021B (en) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
ES2891734T3 (en) | 2014-03-20 | 2022-01-31 | Capella Therapeutics Inc | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for cancer treatment |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
ES2898765T3 (en) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
EP4353311A2 (en) * | 2015-07-20 | 2024-04-17 | The Brigham and Women's Hospital, Inc. | Shear-thinning compositions as an intravascular embolic agent |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10590108B2 (en) * | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EA038635B9 (en) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
CN110036010A (en) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | The inhibitor of KRAS G12C mutain |
EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573971A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
EP3630746A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
TW201900633A (en) | 2017-05-25 | 2019-01-01 | 美商亞瑞克西斯製藥公司 | KRAS covalent inhibitor |
WO2019162323A1 (en) | 2018-02-21 | 2019-08-29 | Boehringer Ingelheim International Gmbh | New benzimidazole compounds and derivatives as egfr inhibitors |
CN108191861B (en) * | 2018-03-01 | 2020-10-02 | 天津大学 | N- [5- (pyrimidin-2-amino) -2, 4-disubstituted-phenyl ] -trans-2, 4-pentadiene-amide |
CN111747931A (en) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | Azaaromatic cyclic amide derivatives for the treatment of cancer |
CN114007698B (en) | 2019-06-24 | 2024-01-09 | 勃林格殷格翰国际有限公司 | Macrocyclic compounds and derivatives as EGFR inhibitors |
JP2023550591A (en) | 2020-11-02 | 2023-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted 1H-pyrazolo[4,3-c] and derivatives as EGFR inhibitors |
WO2022117051A1 (en) * | 2020-12-03 | 2022-06-09 | 北京鞍石生物科技有限责任公司 | Macrocyclic compound, preparation method therefor and use thereof |
WO2024039691A1 (en) * | 2022-08-15 | 2024-02-22 | Nalo Therapeutics, Inc. | N-(1-((r)-1-acryloylazepan-3-yl)-7-chloro-6-(((r)-tetrahydrofuran-3-yl)oxy)-1h-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (nx-019) for use in the treatment of egfr mutant cancer |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (en) | 1990-04-17 | 1994-11-18 | Eurand Int | METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (en) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | Delayed release microsphere of drug |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
AU722289B2 (en) | 1996-10-01 | 2000-07-27 | Aptalis Pharmatech, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
ATE272394T1 (en) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | DELAYED RELEASE PREPARATION |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
DE19648576C2 (en) | 1996-11-23 | 1999-08-12 | Lohmann Therapie Syst Lts | Lozenge for modified release of active substances in the gastrointestinal tract |
ATE233088T1 (en) | 1996-12-20 | 2003-03-15 | Takeda Chemical Industries Ltd | METHOD FOR PREPARING A DELAYED RELEASE COMPOSITION |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (en) | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
US7169410B1 (en) | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
MA26659A1 (en) | 1998-08-06 | 2004-12-20 | Pfizer | NOVEL BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION. |
RU2236847C2 (en) | 1998-11-02 | 2004-09-27 | Илан Корпорейшн, Плк. | Composition as multiple particles with modified release |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
US6623756B1 (en) | 2000-04-27 | 2003-09-23 | Noveon Ip Holdings Corp. | Directly compressed solid dosage articles |
CA2420535A1 (en) | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
ES2351249T3 (en) | 2001-07-27 | 2011-02-02 | Astellas Pharma Inc. | COMPOSITION THAT INCLUDES FINE PARTS, OF SUSTAINED RELEASE, FOR QUICK DISGREGATION TABLETS IN THE ORAL CAVITY. |
ATE404179T1 (en) | 2001-09-28 | 2008-08-15 | Mcneil Ppc Inc | DOSAGE FORMS WITH CORE AND OUTER SHELL |
US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
NZ526926A (en) | 2001-12-19 | 2006-02-24 | Astrazeneca Ab | New film coating composition that provides a latex dispersion for coating pharmaceutical formulations |
US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
US7485322B2 (en) | 2002-12-24 | 2009-02-03 | Lek Pharmaceuticals D.D. | Modified release pharmaceutical composition |
US7427414B2 (en) | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
AU2007332750A1 (en) * | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors containing a tricyclic ring system |
JP2011503076A (en) * | 2007-11-09 | 2011-01-27 | シェーリング コーポレイション | Compounds for inhibiting KSP kinesin activity |
WO2009099982A1 (en) | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
FR2952552B1 (en) * | 2009-11-19 | 2012-01-13 | Commissariat Energie Atomique | DEVICE FOR RECOVERING NANOPOUDERS AND ULTRAFINE POWDERS CONTAINED IN A GAS |
CA2781578A1 (en) | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
KR20130108543A (en) | 2010-08-05 | 2013-10-04 | 암젠 인코포레이션 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
AU2012339679A1 (en) | 2011-11-14 | 2014-06-12 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with BRAF inhibitors |
RU2014119150A (en) | 2011-11-14 | 2015-12-27 | Тесаро, Инк. | MODULATION OF SOME TYROZINKINASES |
EP2849751A1 (en) | 2012-05-10 | 2015-03-25 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
JO3300B1 (en) * | 2012-06-06 | 2018-09-16 | Novartis Ag | Compounds and compositions for modulating egfr activity |
WO2013184766A1 (en) * | 2012-06-06 | 2013-12-12 | Irm Llc | Compounds and compositions for modulating egfr activity |
US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
BR112014032581A8 (en) | 2012-06-27 | 2018-08-14 | 4Sc Discovery Gmbh | Bifluorodioxalan-amino-benzimidazole kinase inhibitors for the treatment of cancer, CNS disorders and autoimmune inflammation |
JP2015526520A (en) * | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Benzimidazole derivatives as ITK inhibitors |
WO2015134210A1 (en) | 2014-03-03 | 2015-09-11 | Principia Biopharma, Inc. | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS |
ES2891734T3 (en) | 2014-03-20 | 2022-01-31 | Capella Therapeutics Inc | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for cancer treatment |
CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
CN104447765A (en) | 2014-12-31 | 2015-03-25 | 深圳铂立健医药有限公司 | Tricyclic compound and pharmaceutical compositions thereof and application thereof |
WO2016126819A1 (en) | 2015-02-03 | 2016-08-11 | Dolby Laboratories Licensing Corporation | Optimized virtual scene layout for spatial meeting playback |
US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
-
2015
- 2015-03-19 ES ES15717994T patent/ES2891734T3/en active Active
- 2015-03-19 EP EP15717994.6A patent/EP3119762B9/en active Active
- 2015-03-19 IL IL291000A patent/IL291000B2/en unknown
- 2015-03-19 CN CN202210345304.6A patent/CN114989140A/en active Pending
- 2015-03-19 CN CN201580023803.1A patent/CN106536506A/en active Pending
- 2015-03-19 CA CA2943220A patent/CA2943220C/en active Active
- 2015-03-19 MX MX2016012097A patent/MX2016012097A/en active IP Right Grant
- 2015-03-19 TW TW104108911A patent/TWI683813B/en active
- 2015-03-19 PT PT157179946T patent/PT3119762T/en unknown
- 2015-03-19 DK DK15717994.6T patent/DK3119762T3/en active
- 2015-03-19 EP EP21173958.6A patent/EP3922630A1/en active Pending
- 2015-03-19 KR KR1020167028920A patent/KR102416358B1/en active IP Right Grant
- 2015-03-19 CA CA3175724A patent/CA3175724C/en active Active
- 2015-03-19 RU RU2016141052A patent/RU2741914C2/en active
- 2015-03-19 SG SG11201607706SA patent/SG11201607706SA/en unknown
- 2015-03-19 KR KR1020227022282A patent/KR20220100081A/en active IP Right Grant
- 2015-03-19 CN CN202210345286.1A patent/CN114940673A/en active Pending
- 2015-03-19 JP JP2017501110A patent/JP6577012B2/en active Active
- 2015-03-19 WO PCT/US2015/021455 patent/WO2015143148A1/en active Application Filing
- 2015-03-19 RU RU2021101430A patent/RU2021101430A/en unknown
- 2015-03-19 TW TW108147560A patent/TWI807150B/en active
- 2015-03-19 US US15/126,997 patent/US10005765B2/en active Active
- 2015-03-19 AU AU2015231202A patent/AU2015231202B9/en active Active
-
2016
- 2016-09-15 IL IL247852A patent/IL247852B/en active IP Right Grant
- 2016-09-19 MX MX2020012165A patent/MX2020012165A/en unknown
-
2018
- 2018-06-11 US US16/005,490 patent/US10647707B2/en active Active
-
2019
- 2019-08-21 JP JP2019151001A patent/JP7073316B2/en active Active
-
2020
- 2020-05-05 US US16/867,451 patent/US11787788B2/en active Active
-
2021
- 2021-04-26 IL IL282651A patent/IL282651B/en unknown
-
2022
- 2022-05-11 JP JP2022078150A patent/JP7394168B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291000A (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
IL279258B (en) | Tyrosine kinase inhibitors | |
HK1256857A1 (en) | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors | |
HK1247202A1 (en) | Compounds for the treatment of cancer | |
HK1258779A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
IL253945B (en) | Kdm1a inhibitors for the treatment of disease | |
PL3218378T3 (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | |
EP3019491A4 (en) | Kinase inhibitors for the treatment of disease | |
EP3247692A4 (en) | Inhibitors of trka kinase | |
IL261015A (en) | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | |
IL248789A0 (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors | |
IL285077A (en) | Compounds for treatment of cancer | |
LT3386991T (en) | Polycyclic compounds as inhibitors of bruton`s tyrosine kinase | |
EP3131552A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
EP3145512A4 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
EP3226869A4 (en) | Kinase inhibitor prodrug for the treatment of cancer | |
IL252200B (en) | Process for the purification of the axl tyrosine receptor kinase inhibitor " r428" | |
IL247867A0 (en) | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | |
HK1205500A1 (en) | Kinase inhibitors for the treatment of cancer | |
PL3364971T3 (en) | Heterocyclic pdk1 inhibitors for use to treat cancer | |
EP3131550A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
ZA201704589B (en) | Compounds for the treatment of cancer |